

ASX ANNOUNCEMENT

13 November 2023

Results of Annual General Meeting

Melbourne, Australia; 13 November 2023: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises that its Annual General Meeting of Shareholders was held today at the Amora Hotel Riverwalk Melbourne, 649 Bridge Road, Richmond VIC 3121 at 11.00 am AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

Resolutions 1 to 10 were passed on a poll, with Resolution 3 (Approval of 10% Placement Facility) and Resolution 10 (Renewal of Proportional Takeover Approval Provisions) being passed by a sufficient majority as special resolutions.

Further information required by section 251AA(2) of the *Corporations Act 2001 (Cth)* is attached.

-ENDS-

Authorised for release by Dr Kilian Kelly, CEO & Managing Director

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

Disclosure of Proxy Votes

Cynata Therapeutics Limited

Annual General Meeting

Monday, 13 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	77,814,757	60,338,484 77.54%	15,648,278 20.11%	54,129	1,827,995 2.35%	64,685,244 80.52%	15,648,278 19.48%	54,129	-
2 Re-election of Dr Darryl Maher as a Director	P	78,540,397	64,190,934 81.73%	12,517,191 15.94%	230,619	1,832,272 2.33%	68,591,971 84.57%	12,517,191 15.43%	230,619	Passed
3 Approval of 10% Placement Facility	P	78,558,620	64,005,397 81.47%	12,676,202 16.14%	212,396	1,877,021 2.39%	68,451,183 84.37%	12,676,202 15.63%	212,396	Passed
4 Approval of Issue of Equity Securities under Employee Incentive Plan	P	77,819,012	60,229,014 77.40%	15,762,003 20.25%	49,874	1,827,995 2.35%	64,575,774 80.38%	15,762,003 19.62%	49,874	Passed
5 Approval of issue of Options to Dr Geoff Brooke	P	77,842,257	60,134,461 77.25%	15,879,801 20.40%	26,629	1,827,995 2.35%	64,481,221 80.24%	15,879,801 19.76%	26,629	Passed
6 Approval of issue of Options to Dr Paul Wotton	P	77,842,257	60,094,461 77.20%	15,919,801 20.45%	26,629	1,827,995 2.35%	64,441,221 80.19%	15,919,801 19.81%	26,629	Passed
7 Approval of issue of Options to Ms Janine Rolfe	P	77,842,257	60,134,461 77.25%	15,879,801 20.40%	26,629	1,827,995 2.35%	64,481,221 80.24%	15,879,801 19.76%	26,629	Passed
8 Approval of issue of Options to Dr Darryl Maher	P	77,842,257	61,269,827 78.71%	14,744,435 18.94%	26,629	1,827,995 2.35%	65,616,587 81.65%	14,744,435 18.35%	26,629	Passed



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of issue of Options to Dr Kilian Kelly	P	77,842,257	61,269,827 78.71%	14,744,435 18.94%	26,629	1,827,995 2.35%	65,616,587 81.65%	14,744,435 18.35%	26,629	Passed
10 Renewal of Proportional Takeover Approval Provisions	P	78,538,703	65,341,878 83.20%	11,315,367 14.41%	232,313	1,881,458 2.40%	69,792,101 86.05%	11,315,367 13.95%	232,313	Passed

